Medical Patent Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Patents
Ligand Pharmaceuticals Awarded U.S. Patent for LGD-4665
January 25th, 2008
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (the Company or Ligand) announced that the United States Patent and Trademark Office issued U.S. Patent No. 7,314,887, titled "Thrombopoietin Activity Modulating Compounds and Methods," to Ligand for LGD-4665, the Company's lead thrombopoietin (TPO) receptor agonist and a family of related compounds. The patent describes LGD-4665 and other small-molecule TPO mimetic compounds discovered at Ligand, formulations involving these compounds, as well as methods of making and using the compounds and formulations. The Patent Scorecard--Quarterly Leader Board report, issued on 11/30/2007, listed Ligand Pharmaceuticals...
Source: Medical Patent Business Week (2008-01-25)
|
